Holy crap, this article on Seeking has everything I have learned about MNKD in the last two years and then some, and then some more.
It has a very pro-MNKD slant but backs its agruments up with graphics, quotes from conferneces and other sources of info. It does mention near the end some of the risks but seems to consider these mute when compared to the potential. Gives a buyout target price of $43 based upon a P/E mulitplier of 16, share of 550M, and Euro + NA revenues of $24B. Here's the excerpt:
"We believe MannKind will have a partner before data is released only if it pays top dollar, as if it has seen the trial results, and they are indeed superior. Otherwise, with superior data, we think it partners soon after the August release.
Either way, we will calculate its share price using 550 million shares to factor in any possible dilution. $24 billion / 550 million shares is $43.64 per share.
Everything has to go right for MannKind, there is a lot of risk involved, and MannKind has had surprises in the past. But we believe that Afrezza is indeed a superior product, and a game changer in type 2 diabetes..."
Reccommend you give it a read or pass it along to anyone thinking about getting into MNKD investment.
Saw we were up in premarket by $.09 this morning, wonder if this article had anything to do with that. Anyways looks like it will be an interesting day.
Enjoy the ride,
OOG
